Novavax Delays to Seek Approval of its Covid-19 Vaccine in US


On Thursday, 5th August 2021, the company ‘Novavax’ has delayed the timeline of the company for the purpose of seeking the authorization of the United States for the company’s two-dose novel corona virus vaccine but, it is also expecting to become one of the major distributors to the low-income and medium-income countries in 2021.

Previously, the company ‘Novavax’ said, it is going to seek the emergency authorization (EUA) from the US FDA in the third quarter of the year 2021, but now its is expected that, the company will be filing the approval in the fourth quarter of the year 2021, and the shares of the company Novavax have been decreased by around 7 percent in the after trade.

Stanley Erck, chief executive of the company ‘Novavax’ said, it has been a matter of getting into the validation work done, for the purpose of demonstrating the consistency in the manufacturing process of the corona virus vaccine to the US FDA, and he also said that, the vaccine regulators of the other countries have been more aggressive in the process of moving the vaccine produced by Novavax through the process of authorization.

READ  Apple Planning to Introduce Contactless Payments Via Tap to Pay on iPhone

Stanley Erck added that, initially, the doses of the Novavax vaccine might be prioritized the countries with low-income, where they all had been able to provide support to the critical demand for the primary vaccinations in the countries, and the company has still remained on the production of 100 million doses each month in the ongoing quarter of the year 2021.